The company impresses investors, but money’s running short.

Imlunestrant monotherapy only works in ESR1 mutants, but a Verzenio combo is better in all-comers.

AZD0486 seems highly active, including in patients relapsed on Car-T therapy.

Much has been made of anito-cel’s rivalry with Carvykti, but Arcellx reckons there’s plenty of market for both.

The Aquila study could make Darzalex the first approved drug for smouldering multiple myeloma.

But with Brukinsa and degraders looming, will fixed dosing make the difference?